Base de dados : LILACS
Pesquisa : E01.370.225.875.950 [Categoria DeCS]
Referências encontradas : 501 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 51 ir para página                         

  1 / 501 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1048106
Autor: Vieira, Tamyres dos santos; Vieira, Isabela dos Santos; Bresser, Matheus; Moura, Letícia Coutinho Lopes; Moura, Marcos de Assis.
Título: O papel do dolutegravir na terapia antiretroviral / The role of dolutegravir in antiretroviral therapy
Fonte: HU rev;44(3):379-385, 2018.
Idioma: pt.
Resumo: os inibidores da integrase são a mais nova classe de antirretroviral aprovada, que agem impedindo a incorporação do DNA do HIV no genoma do linfócito T CD4+ (LTCD4+) do hospedeiro, limitando a propagação do vírus. o Dolutegravir e o inibidor da integrase mais moderno e como os demais inibidores apresenta de alta performance, boa tolerância; alta barreira genética para mutações de resistência, além de apresentar eficácia em pacientes já submetidos a tratamento antirretroviral anterior. Neste contexto o presente estudo trata-se de um estudo de revisão bibliográfica realizada de janeiro a junho de 2018, de artigos científicos de artigos científicos que abordam aspectos exclusivos do dolutegravir na terapia antirretroviral em comparação com outros esquemas terapêuticos. Concluindo que o tratamento com dolutegravir apresenta como principais vantagens à rápida supressão virológica; boa tolerância e alta barreira genética para mutações de resistência.

Integrase inhibitors are the newest class of approved antiretroviral drugs that act by preventing the incorporation of HIV DNA into the CD4 + T lymphocyte (LTCD4 +) genome of the host, limiting the spread of the virus. Dolutegravir and the most modern integrase inhibitor and like the other inhibitors presents high performance, good tolerance; high genetic barrier for resistance mutations, in addition to being effective in patients already submitted to previous antiretroviral treatment. In this context, the present study is a bibliographical review study conducted from January to June, 2018, of scientific papers on scientific articles dealing with exclusive aspects of dolutegravir in antiretroviral therapy compared to other therapeutic regimens. Concluding that dolutegravir treatment has the main advantages of rapid virological suppression; good tolerance and high genetic barrier for resistance mutations
Descritores: HIV
Terapia Antirretroviral de Alta Atividade
-Preparações Farmacêuticas
Síndrome de Imunodeficiência Adquirida
Inibidores de Integrase
Integrases
Carga Viral
Antirretrovirais
Tipo de Publ: Relatos de Casos
Responsável: BR378.1 - Biblioteca Central


  2 / 501 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Lemos, Marcílio Figueiredo
Moreira, Regina Celia
Texto completo
Id: biblio-1123203
Autor: Alves, Fabiana Aparecida; Campos, Karoline Rodrigues; Lemos, Marcílio Figueiredo; Moreira, Regina Célia; Caterino-de-Araujo, Adele.
Título: Hepatitis C viral load in HCV-monoinfected and HCV/HIV-1-, HCV/HTLV-1/-2-, and HCV/HIV/HTLV-1/-2-co-infected patients from São Paulo, Brazil
Fonte: Braz. j. infect. dis;22(2):123-128, Mar. apr. - 2018. mapas, tab, graf.
Idioma: en.
Resumo: Co-infections of hepatitis C virus (HCV) and either human immunodeficiency virus type1 (HIV-1), human T-cell lymphotropic virus type 1 (HTLV-1) or type 2 (HTLV-2) have beendescribed as having an impact on HCV viremia and subsequent disease progression. HCVload in serum samples from 622 patients (343 males, 279 females; median age 50.8 years)from São Paulo/southeast Brazil was analyzed using the Abbott Real Time HCV assay(Abbott Molecular Inc., IL, USA). Samples were obtained from HCV-monoinfected (n = 548),HCV/HIV-1- (n = 41), HCV/HTLV-1- (n = 16), HCV/HTLV-2- (n = 8), HCV/HIV/HTLV-1- (n = 4), andHCV/HIV/HTLV-2-co-infected (n = 5) patients, and results were compared among the groupsand according to sex. The median HCV load in HCV-monoinfected patients was 5.23 log10IU/mL and 0.31 log10higher in men than in women. Increases in viral load of 0.51 log10, 0.54log10, and 1.43 log10IU/mL were detected in HCV/HIV-1-, HCV/HTLV-1- and HCV/HIV/HTLV-1-co-infected individuals, respectively, compared with HCV-monoinfected counterparts. Incontrast, compared to HCV/HIV co-infected patients, HCV/HTLV-2-co-infected patients hadan HCV load of 5.0 log10IU/mL, whereas HCV/HIV/HTLV-2-co-infected patients had a medianload 0.37 log10IU/mL lower. Significant differences in HCV loads were detected, with malesand HCV/HIV-1- and HCV/HIV/HTLV-1-co-infected patients presenting the highest values.Conversely, females and HCV/HTLV-2-co-infected patients exhibited lower HCV loads. Over-all, HCV viremia is increased in HIV and/or HTLV-1-co-infection and decreased in HTLV-2co-infection. (AU)
Descritores: Pacientes
Brasil
HIV-1
HIV
Hepatite C
Hepacivirus
Carga Viral
Coinfecção
Limites: Humanos
Masculino
Feminino
Responsável: BR91.2 - Centro de Documentação


  3 / 501 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887635
Autor: Rateni, Liliana; Lupo, Sergio; Racca, Liliana; Palazzi, Jorge; Ghersevich, Sergio.
Título: Assessing endocrine and immune parameters in human immunodeficiency virus-infected patients before and after the immune reconstitution inflammatory syndrome
Fonte: Arch. endocrinol. metab. (Online);62(1):64-71, Jan.-Feb. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective The present study compares immune and endocrine parameters between HIV-infected patients who underwent the Immune Reconstitution Inflammatory Syndrome (IRIS-P) during antiretroviral therapy (ART) and HIV-patients who did not undergo the syndrome (non-IRIS-P). Materials and methods Blood samples were obtained from 31 HIV-infected patients (15 IRIS-P and 16 non-IRIS-P) before ART (BT) and 48 ± 2 weeks after treatment initiation (AT). Plasma Interleukin-6 (IL-6) and Interleukin-18 (IL-18) were determined by ELISA. Cortisol, dehydroepiandrosterone sulfate (DHEA-S) and thyroxin concentrations were measured using chemiluminescence immune methods. Results Concentrations of IL-6 (7.9 ± 1.9 pg/mL) and IL-18 (951.5 ± 233.0 pg/mL) were significantly higher (p < 0.05) in IRIS-P than in non-IRIS-P (3.9 ± 1.0 pg/mL and 461.0 ± 84.4 pg/mL, respectively) BT. Mean T4 plasma level significantly decreased in both groups of patients after treatment (p < 0.05). In both groups cortisol levels were similar before and after ART (p > 0.05). Levels of DHEA-S in IRIS-P decreased AT (1080.5 ± 124.2 vs. 782.5 ± 123.8 ng/mL, p < 0.05) and they were significantly lower than in non-IRIS-P (782.5 ± 123.8 vs. 1203.7 ± 144.0 ng/mL, p < 0.05). IRIS-P showed higher values of IL-6 and IL-18 BT and lower levels of DHEA-S AT than in non-IRIS-P. Conclusion These parameters could contribute to differentiate IRIS-P from non-IRIS-P. The significant decrease in DHEA-S levels in IRIS-P after ART might suggest a different adrenal response in these patients, which may reflect the severity of the disease.
Descritores: Biomarcadores/sangue
Infecções por HIV/sangue
Terapia Antirretroviral de Alta Atividade/efeitos adversos
Síndrome Inflamatória da Reconstituição Imune/sangue
-Tiroxina/sangue
Ensaio de Imunoadsorção Enzimática
Hidrocortisona/sangue
Infecções por HIV/imunologia
Infecções por HIV/metabolismo
Infecções por HIV/tratamento farmacológico
Estudos Prospectivos
Interleucina-6/sangue
Relação CD4-CD8
Sulfato de Desidroepiandrosterona/sangue
Carga Viral
Interleucina-18/sangue
Luminescência
Síndrome Inflamatória da Reconstituição Imune/imunologia
Síndrome Inflamatória da Reconstituição Imune/metabolismo
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  4 / 501 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1042208
Autor: Almeida, Elton Carlos de; Gleriano, Josué Souza; Pinto, Flavia Kelli Alvarenga; Coelho, Ronaldo de Almeida; Vivaldini, Simone Monzani; Gomes, José Nilton Neris; Santos, Alexandre Fonseca; Sereno, Leandro Soares; Pereira, Gerson Fernando Mendes; Henriques, Sílvia Helena; Chaves, Lucieli Dias Pedreschi.
Título: Access to viral hepatitis care: distribution of health services in the Northern region of Brazil / Acesso à atenção às hepatites virais: distribuição de serviços na região Norte do Brasil
Fonte: Rev. bras. epidemiol;22(supl.1):e190008, 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective: To analyze the distribution of health care services for viral hepatitis and reported cases of viral hepatitis according to the health regions of Northern Brazil. Method: It is an evaluative, descriptive and quantitative research considering viral hepatitis care services and reported cases in the Northern region of Brazil, using data collected from the National Registry of Health Establishments and the Notifiable Diseases Information System. Descriptive statistics and georeferencing, through software, were used to demonstrate the spatial distribution of services and reported cases. Results: Viral hepatitis health services are distributed in a differentiated way; rapid tests are capillaries in the states; confirmatory tests and treatment are performed in some health regions, with a greater grouping of services in the capitals and their surroundings. Cases were reported across all regions, with areas of higher concentration near services. Conclusion: The availability of services can favor access to prevention, diagnosis and monitoring of cases. However, organizational peculiarities of the health system and services highlight fragilities that have repercussions on the access and entirety of viral hepatitis care.

RESUMO Objetivo: Analisar a distribuição dos serviços de saúde de atenção às hepatites virais e os casos notificados de hepatites virais segundo as regiões de saúde dos estados do Norte do Brasil. Método: Trata-se de pesquisa avaliativa, descritiva e quantitativa considerando os serviços de atenção e casos notificados de hepatites virais na região Norte do Brasil. Foram coletados dados do Cadastro Nacional de Estabelecimentos de Saúde e do Sistema de Informação de Agravos e Notificação. Utilizou-se estatística descritiva e georreferenciamento por meio de software para visualizar a distribuição espacial dos serviços e os casos notificados. Resultados: Os serviços são distribuídos de maneira diferenciada; testes rápidos apresentam-se capilarizados nos estados; demais exames para confirmar o diagnóstico e o tratamento são realizados em algumas regiões de saúde, com maior agrupamento de serviços nas capitais e suas cercanias. Verificam-se casos notificados de maneira pulverizada nas regiões, com áreas de maior concentração próximas aos serviços. Conclusão: A disponibilidade de serviços pode favorecer o acesso e a adoção de medidas de prevenção, diagnóstico e monitoramento de casos. Entretanto, peculiaridades organizacionais do sistema e serviços de saúde evidenciam fragilidades que repercutem no acesso e na integralidade da atenção às hepatites virais.
Descritores: Serviços de Saúde/estatística & dados numéricos
Acesso aos Serviços de Saúde/estatística & dados numéricos
Hepatite Viral Humana/epidemiologia
-Fatores Socioeconômicos
Brasil/epidemiologia
Notificação de Doenças/estatística & dados numéricos
Carga Viral/estatística & dados numéricos
Geografia
Pesquisa sobre Serviços de Saúde
Hepatite Viral Humana/diagnóstico
Limites: Humanos
Responsável: BR1.1 - BIREME


  5 / 501 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-716721
Autor: Santos, Ana Paula de Torres.
Título: Padronização da PCR em Tempo Real para o Diagnóstico da Hepatite B / Standardization of real-time PCR for the hepatitis B diagnosis.
Fonte: São Paulo; s.n; 2014. 99 p. ilus, tab, graf.
Idioma: pt.
Tese: Apresentada a Secretaria da Saúde. Coordenadoria de Controle de Doenças. Programa de Pós-Graduação em Ciências para obtenção do grau de Mestre.
Resumo: A hepatite B é uma doença de interesse em saúde pública, acometendo cerca de 2 bilhões de pessoas no mundo, das quais aproximadamente 350 milhões tornam-se portadoras crônicas. Os ensaios quantitativos de detecção do DNA viral são empregados para avaliar a infectividade do vírus e para o monitoramento do tratamento, sendo importante para avaliar a progressão da doença. O objetivo deste estudo foi padronizar a técnica de amplificação quantitativa em tempo real (PCR em tempo real) do DNA do vírus da Hepatite B e comparar a técnica com métodos comerciais (COBAS AmpliPrep/COBAS TaqMan® e COBAS AmpliPrep/COBAS TaqMan®). A amostragem foi constituída por 397 amostras de soro ou plasma recebidas e estocadas no laboratório de hepatites virais do Centro de Virologia do Instituto Adolfo Lutz, no período de 2009 a 2011. Do total de amostras, 345 foram utilizadas para a comparação com os testes comerciais disponíveis e 52 amostras foram utilizadas para o teste de especificidade, sendo 27 amostras HIV positivas e 25 amostras HCV positivas, todas com AgHBS e Anti-HBc total não reagentes. Estas amostras foram inicialmente analisadas por testes comerciais e posteriormente pela técnica padronizada. Para o controle da quantificação, uma curva padrão foi construída em todas as reações, utilizando-se padrões internacionais produzidos pela Organização Mundial de Saúde, em diluições seriadas. Para a extração do DNA das amostras e padrão, foi utilizado kit comercial (QIAGEN®), seguindo os procedimentos descritos pelo fabricante. Os testes foram realizados empregando o método do TaqMan – PCR, em um equipamento ABI 7300 (Applied Biosystems, Foster City, CA). Os “primers” e sondas utilizadas para a padronização foram selecionados a partir da literatura e os que apresentaram melhores resultados nos testes iniciais foram escolhidos para o estudo. A técnica de sequenciamento foi realizada nas amostras com carga viral quantificável...

Hepatitis B is a disease of public health concern. Worldwide, it affects approximately 2 billion people, of whom approximately 350 million become chronic carriers. Quantitative assays for the detection of viral DNA are used to evaluate the infectivity of the virus and to monitor treatment, which is crucial to evaluate the progression of the disease. The aim of this study was to standardize real-time (real-time PCR) quantitative amplification of the DNA of hepatitis B and to compare this technique with commercial methods (COBAS AmpliPrep / COBAS ® TaqMan and COBAS AmpliPrep / COBAS TaqMan ®). The sample consisted of 397 serum or plasma samples received and stored at the laboratory of viral hepatitis from the Center of Virology, Instituto Adolfo Lutz, from 2009 to 2011. Of the total samples, 345 were used for comparison with the available commercial tests and 52 samples were used for the specificity test. Of these, 27 were HIV positive and 25, HCV positive, and all were HBsAg and anti- HBc nonreactive. These samples were initially analyzed by commercial tests and later by the standardized technique. To control the quantification, a standard curve was constructed in all reactions using international standards established by the World Health Organization, in serial dilutions. For the extraction of DNA samples and standard, a commercial kit used was (QIAGEN ®) according to the manufacturer's instructions. The tests were performed using the TaqMan method - ABI 7300 PCR system (Applied Biosystems, Foster City, CA). Primers and probes used for standardization were selected from the literature and those presenting better results in initial tests were chosen for the study. Sequencing technique was performed on samples with measurable viral load. The standardized real-time PCR technique yielded satisfactory results...
Descritores: Carga Viral/métodos
DNA Viral
Genótipo
Hepatite B/diagnóstico
Orthohepadnavirus
Reação em Cadeia da Polimerase em Tempo Real
Limites: Humanos
Tipo de Publ: Estudo Comparativo
Responsável: BR91.2 - Centro de Documentação
BR91.2; W4, S237p


  6 / 501 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Lemos, Marcílio Figueiredo
Moreira, Regina Celia
Texto completo
Id: biblio-1092220
Autor: Caterino-de-Araujo, Adele; Campos, Karoline Rodrigues; Petrucci, Tamirez Villas Boas; Silva, Rafael Xavier da; Lemos, Marcílio Figueiredo; Moreira, Regina Célia.
Título: Surveillance of human retroviruses in blood samples from patients with hepatitis B and C in São Paulo, Brazil
Fonte: Rev. Soc. Bras. Med. Trop;53:e20190378, 2020. tab, graf.
Idioma: en.
Projeto: Fundação de Amparo a Pesquisa de São Paulo; . Conselho Nacional de Desenvolvimento Científico e Tecnológico; . CNPq.
Resumo: Abstract INTRODUCTION Human retroviruses and the hepatitis B and C viruses (HBV and HCV, respectively) share routes of transmission; thus, coinfections occur and could alter subsequent disease outcomes. A preliminary study on human T-lymphotropic virus types 1 and 2 (HTLV-1/2) in serum samples from HBV- and HCV-infected individuals in São Paulo revealed 1.3% and 5.3% rates of coinfection, respectively. These percentages were of concern since they were detected in HTLV-endemic regions and in high-risk individuals in Brazil. The present study was conducted to extend and confirm these data. METHODS HTLV-1/2 and human immunodeficiency virus (HIV) infection status were identified in 1,984 sera for HBV and HCV viral load quantification - 1,290 samples from HBV-infected individuals (53.3% men, mean age: 47.1 years) and 694 samples from HCV-infected individuals (56.3% men, mean age: 50.1 years). HTLV-1/2 antibodies were detected by enzyme immunoassay, followed by western blotting and line immunoassay; HIV infection was detected by enzyme immunoassay. RESULTS HTLV-1/-2 infection was detected in 1.9% HBV-infected individuals (0.7% HTLV-1 and 1.2% HTLV-2) and in 4.0% (2.4% HTLV-1 and 1.6% HTLV-2) HCV-infected individuals; HIV infection was detected in 9.2% and 14.5%, respectively. Strong associations with HTLV and HIV, male sex, and older age were found in HBV/HTLV and HCV/HTLV-coinfected individuals (p<0.05). CONCLUSIONS HTLV-1 and HTLV-2 were confirmed to be prevalent in individuals with HBV and HCV in São Paulo; coinfected individuals deserve further clinical and laboratory investigation.
Descritores: Sexo
HIV
Carga Viral
Hepatite B
Infecções
Métodos
Responsável: BR91.2 - Centro de Documentação


  7 / 501 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-886661
Autor: MÜLLER, TALISE E; ELLWANGER, JOEL H; MICHITA, RAFAEL T; MATTE, MARIA CRISTINA C; RENNER, JANE D P.
Título: CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil
Fonte: An. acad. bras. ciênc;89(1,supl):497-504, May. 2017. tab.
Idioma: en.
Resumo: ABSTRACT This study aimed to identify the 516 G>T polymorphism of the CYP2B6 gene and evaluate its influence on central nervous system (CNS) side effect development in HIV-positive individuals undergoing Efavirenz (EFV) treatment in a population from southern Brazil. Additionally, we performed a survey on the clinical and epidemiological characteristics of our sample. In addition to medical records evaluation, whole blood of 89 individuals was analyzed for viral load, T lymphocyte count (CD4+ and CD8+), and the polymorphism. Considering the side effects of the CNS reported by individuals but without considering the genetic variables, no statistically significant association was noted between the adverse effects and the antiretroviral treatment (including or not EFV). In addition, no statistically significant difference was noted for the influence of genotype on the viral load or the number of T lymphocytes (CD4+ and CD8+) among individuals undergoing EFV treatment. This is the first study that investigated the impact of the 516 G>T polymorphism of the CYP2B6 gene among HIV-positive individuals from southern Brazil. Its clinical significance indicates the need for prospective studies in this population.
Descritores: Polimorfismo Genético/genética
Infecções por HIV/genética
Infecções por HIV/tratamento farmacológico
Sistema Nervoso Central/efeitos dos fármacos
Inibidores da Transcriptase Reversa/efeitos adversos
Benzoxazinas/efeitos adversos
Citocromo P-450 CYP2B6/genética
-Estudos Prospectivos
Relação CD4-CD8
Inibidores da Transcriptase Reversa/uso terapêutico
Carga Viral
Benzoxazinas/uso terapêutico
Genótipo
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  8 / 501 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-224919
Autor: Scerpella, Ernesto; Campos, Rafael.
Título: Avances recientes en VIH/SIDA: terapia antiretroviral / Recent advances in HIV/AIDS: antiretroviral therapy
Fonte: Rev. méd. hered;8(1):23-31, mar. 1997. tab, graf.
Idioma: es.
Resumo: Recent advances in our understanding of the pathogenesis of HIV infection in patients with the acquired immunodeficiency syndrome (AIDS) are leading us to explore new treatment strategies, including the use of combination antiretroviral therapy. In this review, we present information from recently completed clinical trials that explore the use of combination therapy, including ACTG 175, the Delta studies, and the NUCA studies. In addition, we present preliminary information about the use of protease inhibitors, the newest class of antiretrovirals.
Descritores: Reação em Cadeia da Polimerase
HIV
Carga Viral
Síndrome de Imunodeficiência Adquirida/genética
Síndrome de Imunodeficiência Adquirida/terapia
Tipo de Publ: Revisão
Responsável: PE1.1 - Oficina Universitária de Biblioteca


  9 / 501 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-224662
Autor: Campo, Rafael E; Scerpella, Ernesto G.
Título: Avances recientes en HIV-SIDA: patogénesis, historia natural y carga viral / Recent developments in HIV/SIDA: pathogenesis, natural history and viral load
Fonte: Rev. méd. hered;7(4):182-8, dic. 1996. tab.
Idioma: es.
Resumo: Results of recent research investigations have given us a new understanding of the pathogenesis of HIV infection. This findings provide us with a kinetic model of pathogenesis in which continuous, high grade viral replication is the principal force driving the destruction of CD4 lymphocytes. This knowledge will lead us to design better treatment strategies directed to curtail viral replication and prevent the emergence of viral resistance, and the use of combination antiretroviral therapy is a first example of these new strategies. The concept of viral load is introduced, and we discuss the usefulness of viral load in the clinical prognosis of this disease, and its use as an aid in the decision making process when starting or modifying antiretroviral therapy in our patients.
Descritores: HIV/patogenicidade
Carga Viral
Síndrome de Imunodeficiência Adquirida
Limites: Humanos
Tipo de Publ: Revisão
Responsável: PE1.1 - Oficina Universitária de Biblioteca


  10 / 501 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-533809
Autor: Chirinos de Rivero, Luis Fernando; Campos Nizama, Juan; Castro Valdivia, Raúl; Valdez Herrera, Jesús.
Título: Perfil epidemiológico de los pacientes con Hepatitis Crónica por virus C y su respuesta virológica temprana al tratamiento con Interferón Pegilado más Ribavirina. Servicio de Gastroenterología, HNCASE ESSALUD Arequipa 2004-2006 / Epidemic profile of the patients with Chronic Hepatitis for virus C and its early virological answer to the treatment with Pegilated Interferon more Ribavirina. Service of Gastroenterology, HNCASE ESSALUD Arequipa 2004-2006
Fonte: Rev. gastroenterol. Perú;27(1):47-56, ener.-mar. 2007. tab, graf.
Idioma: es.
Resumo: Se realizó el presente estudio descriptivo retrospectivo y longitudinal para determinar el perfil epidemiológico de los pacientes infectados por virus de hepatitis C con hepatitis crónica, así como la evaluación de sus criterios de legibilidad para recibir tratamiento con Interferón Pegilado más Ribavirina y su respuesta virológica temprana al tratamiento. Se estudiaron 20 pacientes atendidos en el Servicio de Gastroenterología del Hospital Carlos Seguín Escobedo de EsSalud entre los años 2004 y 2006. El diagnóstico de infección por HVC se confirmó mediante la detección de DNA viral mediante PCR, y de la carga viral mediante el conteo de número de copias. Se determinaron los criterios de legibilidad para tratamiento antiviral; se empleó además el score METAVIR para determinar la presencia de fibrosis hepática. Luego de 12 semanas de tratamiento se evaluó a los pacientes que cumplieron criterios de elegibilidad y que accedieron al tratamiento y se evaluó su efectividad mediante una nueva determinación de la carga viral. Hubo más pacientes mujeres (15; 75 por ciento) que varones (5; 25 por ciento), con edades entre 50 y 59 años. El antecedente de riesgo más frecuente fue transfusión sanguínea (45 por ciento), cirugía (35 por ciento), y accidentes de trabajo (10 por ciento). Los valores de parámetros hematológicos, renal y hormonal estuvieron dentro de límites normales, los parámetros de función hepática (bilirrubinas, aminotransferasas, fosfatasa alcalina y gamaglutamil transpeptidasa) estuvieron por encima de lo normal; la carga viral al momento del diagnóstico fue en promedio de 580 mil copias (entre 4100 a 2 millones de copias). Los genotipos virales más frecuentes fueron 1a y 1b. Hasta 40 por ciento de pacientes no tuvieron criterios de elegibilidad para recibir tratamiento antiviral. Sólo 9 a 12 pacientes que tuvieron criterios de tratamiento lo recibieron (75 por ciento), en 6 de ellos se evaluó la respuesta virológica temprana y de ellos...

The present descriptive, retrospective and longitudinal study was designed todetermine the epidemic profile of patients infected by hepatitis C virus and chronic hepatitis, as well as to describe the eligibility criteria for treatment with pegilated interferon plus ribavirina and its early virological answer to the treatment. We studied 20 patients treated at Gastroenterology Service of Carlos Seguín Escobedo Hospital of EsSalud between 2004 and 2006. The diagnosis of HVC infection was confirmed by detection of viral RNA with PCR, and the viral load by counting number of RNA copies. The eligibility criteria for antiviral treatment were determined, and also the METAVIR score to determine hepatic fibrosis. After 12 weeks of treatment the patients with eligibility criteria and received treatment were evaluated, and theeffectivity of treatment was evaluated with a new determination of viral load.There were more female (15; 75 per cent) than male patients (5; 25 per cent), with ages between 50 and 59 years. The more frequent risk antecedent was blood transfusion (45 per cent), surgery (35 per cent), and traffic accident (10 per cent). The hematological, hepatic, renal and hormonal parameters were in normal range; and the viral load at the moment of diagnosis was of 580 thousand copies mean (between 4100 to 2 millions copies). The most frequent viral genotypes were 1a and 1b. Up to 40 per cent of patients did not fulfilled eligibility criteria for treatment. Nine of 12 patients with eligibility criteria received treatment (75 per cent), 6of them were evaluated for early virologc response and of them 100,0 per cent had an early virologic response with decrease of post-therapeutic viral load in all but one cases until non-detectable levels. In conclusion our study described the profile of patients infected by HCV with chronic hepatitis in gastroenterology ward of our hospital, and it has been determined that is suggestive that antiviral treatment is highly...
Descritores: Antivirais
Carga Viral
Hepacivirus
Hepatite C Crônica/epidemiologia
Hepatite C Crônica/terapia
Interferons/uso terapêutico
Ribavirina/uso terapêutico
-Epidemiologia Descritiva
Estudos Longitudinais
Estudos Retrospectivos
Limites: Humanos
Masculino
Adulto
Pessoa de Meia-Idade
Feminino
Responsável: PE1.1 - Oficina Universitária de Biblioteca



página 1 de 51 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde